{"entity":{"id":"nct06439771","kind":"trial","name":"A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC","aka":[],"tldr":"A phase 2 trial of YL202 should be intravenously infused in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.","summary":"A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC is a phase 2 interventional study registered as NCT06439771 by MediLink Therapeutics (Suzhou) Co., Ltd., with 180 participants planned, started 2024-04-23 and due to reach its primary completion in 2026-07-30. Interventions recorded: YL202 should be intravenously infused.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06439771","url":"https://clinicaltrials.gov/study/NCT06439771"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["her2"],"drugs":["yl202"],"companies":["medilink"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06439771","phase":"2","setting":"A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With Locally Advanced or Metastatic Breast Cancer With TNBC, HR-Positive, HER2-Zero-expression or HER2-Low-expression","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","started":"2024-04-23","startedType":"actual","enrolled":180,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06439771/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"yl202","kind":"drug","name":"YL202","route":"/drugs/yl202/"}],"company":[{"id":"medilink","kind":"company","name":"MediLink Therapeutics","route":"/companies/medilink/"}]}}